Advaxis Inc. diskutieren
Advaxis Inc.
WKN: A2PGJ3 / Symbol: ADXS / Name: Advaxis / Aktie / Pharmazeutika / Micro Cap /
Stier
a +
Gebärmutterhalskrebs
6. Februar 2017 Advaxis kündigt die erste Patientenbehandlung in der globalen Phase - 3 - Studie für AIM2CERV hohes Risiko, lokal fortgeschrittenem Gebärmutterhalskrebs
$
Gesundheit | Biotechnologie | Vereinigte Staaten
$
Biotechnologie und medizinische SecteurRecherche
ADXS has very interesting make-or-break potential, caveat emptor!
One can be tentatively optimistic in the ability of ADXS to move the needle in its late-stage clinical programs. Cervical cancer remains a substantial unmet need, and the company is moving aggressively toward filing for approval in Europe. One highly encouraging sign, in my mind, is the tacit endorsement from 3 out of the 5 big immune checkpoint developers. BMY, MRK, and AZN are all collaborating with ADXS in some way. By no means is ADXS the only partner for the immune checkpoints, but this is a positive sign for me.
Cantor Fitzgerald reiterates buy rating with target of $19.00.
https://www.advaxis.com/wp-content/uploads/2017/06/A-recombinant-HER2-Neu.pdf
Biotechnologie und medizinische SecteurRecherche
stratec stimmt der Buy-Einschätzung von tamam zu
stratec stimmt am 24.01.2018 der Buy-Einschätzung von tamam mit dem Kursziel 10$ zu.
Überschrift: ADXS has very interesting make-or-break potential, caveat emptor!
Tolerability of ADXS11-001 Lm-LLO Listeria Based Immunotherapy With Mitomycin, Fluorouracil and Radiation for Anal Cancer
ADXS reports that 8 of 9 patients were progression-free at the 42 months mark. If researchers could reproduce this in a wider patient population, then addition of the Lm-based immunotherapy might represent a new standard of care.
ist das langsam mal der Boden?
SecteurRecherche biotechnologique et médicale Agenda 19/12 Publication de résultats
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of cancer immunotherapies.
It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins.
It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy, and hotspot mutation therapy.
The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.
Nombre d'employés : 108 personnes.
Kaufen
Kaufen
Neueste Beiträge
Wertexplorator in Axactor publ diskutieren